Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Akero Therapeutics stock | $29.11

Own Akero Therapeutics stock in just a few minutes.

Fact checked

Akero Therapeutics, Inc is a biotechnology business based in the US. Akero Therapeutics shares (AKRO) are listed on the NASDAQ and all prices are listed in US Dollars. Akero Therapeutics employs 16 staff and has a market cap (total outstanding shares value) of USD$905.2 million.

How to buy shares in Akero Therapeutics

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Akero Therapeutics. Find the stock by name or ticker symbol: AKRO. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Akero Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$29.11, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Akero Therapeutics, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Akero Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Akero Therapeutics share price

Use our graph to track the performance of AKRO stocks over time.

Akero Therapeutics shares at a glance

Information last updated 2020-12-27.
Latest market closeUSD$29.11
52-week rangeUSD$10.78 - USD$41.16
50-day moving average USD$28.0809
200-day moving average USD$30.8612
Wall St. target priceUSD$60.29
PE ratio 8.1818
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-91.753

Buy Akero Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs, Cryptocurrency
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
$0 for US stocks
Stocks, Options, ETFs
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
TD Ameritrade
or $25 broker-assisted
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Akero Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Akero Therapeutics price performance over time

Historical closes compared with the close of $29.11 from 2020-12-09

1 week (2021-01-07) 15.98%
1 month (2020-12-17) 8.50%
3 months (2020-10-16) 2.68%
6 months (2020-07-16) -21.96%
1 year (2020-01-16) 47.84%
2 years (2019-01-13) N/A
3 years (2018-01-13) N/A
5 years (2016-01-13) N/A

Is Akero Therapeutics under- or over-valued?

Valuing Akero Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Akero Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Akero Therapeutics's P/E ratio

Akero Therapeutics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 8x. In other words, Akero Therapeutics shares trade at around 8x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Akero Therapeutics financials

Gross profit TTM USD$0
Return on assets TTM -18.49%
Return on equity TTM -30.29%
Profit margin 0%
Book value $8.25
Market capitalisation USD$905.2 million

TTM: trailing 12 months

Shorting Akero Therapeutics shares

There are currently 1.9 million Akero Therapeutics shares held short by investors – that's known as Akero Therapeutics's "short interest". This figure is 5.8% up from 1.8 million last month.

There are a few different ways that this level of interest in shorting Akero Therapeutics shares can be evaluated.

Akero Therapeutics's "short interest ratio" (SIR)

Akero Therapeutics's "short interest ratio" (SIR) is the quantity of Akero Therapeutics shares currently shorted divided by the average quantity of Akero Therapeutics shares traded daily (recently around 151579.12698413). Akero Therapeutics's SIR currently stands at 12.6. In other words for every 100,000 Akero Therapeutics shares traded daily on the market, roughly 12600 shares are currently held short.

However Akero Therapeutics's short interest can also be evaluated against the total number of Akero Therapeutics shares, or, against the total number of tradable Akero Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Akero Therapeutics's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Akero Therapeutics shares in existence, roughly 60 shares are currently held short) or 0.1003% of the tradable shares (for every 100,000 tradable Akero Therapeutics shares, roughly 100 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Akero Therapeutics.

Find out more about how you can short Akero Therapeutics stock.

Akero Therapeutics share dividends

We're not expecting Akero Therapeutics to pay a dividend over the next 12 months.

Akero Therapeutics overview

Akero Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for serious metabolic diseases. Its lead product candidate is AKR-001, which is in Phase IIa clinical trial for the treatment of nonalcoholic steatohepatitis disease.The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was founded in 2017 and is headquartered in South San Francisco, California.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site